TFF1 and retinoblastoma: As TFF1 is supposed to be a marker of a subset of more advanced RB tumors with a higher risk for metastases, routinely screening for its expression might also enable a stratification of personalized intervention prior to therapy and monitoring of treatment effectiveness in the course of therapy, as well as detection of metastatic relapses caused by therapy resistance.